1. Frampton, J. E., & Croom, K. F. (2006). Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. Drugs, 66(11), 1501-1512.
2. Kearney, B. P., Flaherty, J. F., & Shah, J. (2004). Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clinical pharmacokinetics, 43(9), 595-612.
3. Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., ... & Cheng, A. K. (2006). Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New England Journal of Medicine, 354(3), 251-260.
4. Dravid, A., Betha, T. P., Sharma, A. K., Gawali, R., Mahajan, U., Kulkarni, M., ... & Rathod, N. (2020). Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India. HIV medicine, 21(9), 578-587.
5. SANKARAIAH, J., SHARMA, N., & NAIM, M. J. (2022). Formulation And Development Of Fixed-Dose Combination Of Bi-Layer Tablets Of Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate Tablets 600 Mg/300 Mg/300 Mg. Int J App Pharm, 14(1), 185-197.